Propafenone is a class 1C antiarrhythmic drug, with sodium channel blocking properties, used in the treatment of atrial fibrillation or ventricular arrhythmias.
Propafenone (Adverse Reactions)
Propafenone is a class Ic antiarrhythmic drug used to treat certain types of cardiac arrhythmias, such as paroxysmal atrial fibrillation and ventricular tachycardias. It works by stabilizing the electrical activity of the heart by blocking sodium channels, helping to restore a normal heart rhythm.
It is administered orally or intravenously and requires medical monitoring, as it can have proarrhythmic effects in some patients.
MECHANISM OF ACTION
Propafenone is an antiarrhythmic that works by blocking sodium channels in heart cells, which leads to a decrease in the excitability of these cells. In addition to this, propafenone has additional beta-blocking activity that can also reduce heart rate.
CONTRAINDICATIONS
Treatment with propafenone is contraindicated in several situations due to its antiarrhythmic and cardiac conduction depressant effect, increasing the risk of sudden death in these cases. These include heart failure, conduction blocks, Brugada syndrome, electrolyte imbalances such as hypokalemia, chronic obstructive pulmonary disease, or severe bronchial asthma.
Propafenone is also contraindicated in patients with hypersensitivity to the drug or its excipients.
The drug should be administered with caution in elderly, diabetic, or hypotensive patients.
SIDE EFFECTS
Like all drugs, propafenone can cause a number of side effects. The most frequently reported include dizziness, irregular heartbeat, or palpitations. Anxiety, difficulty sleeping, headaches, altered taste, blurred vision, difficulty breathing, stomach pain, discomfort, diarrhea, liver disorders, or feeling tired, among others, may also occur, although less frequently.
INTERACTIONS
Propafenone can interact with other drugs. Among the drugs that can increase its levels, increasing the risk of toxicity, are CYP2D6 inhibitors, such as fluoxetine, paroxetine, amiodarone, or quinidine, CYP3A4 inhibitors, such as ketoconazole, ritonavir, or erythromycin, and CYP1A2 inhibitors, such as ciprofloxacin.
Drugs that can decrease propafenone levels and reduce its antiarrhythmic effect include CYP3A4 and CYP1A2 inducers, such as rifampicin, phenobarbital, or carbamazepine.
In addition, the combination of propafenone with other antiarrhythmics such as flecainide, quinidine, or amiodarone, SSRIs, or neuroleptics, may increase the risk of arrhythmia and ventricular block.
BRAND NAMES
- Rythmol®
- Rytmonorm®
Genes analyzed
Bibliography
Tran QT, Baek IH, Han NY, Yun HY, Chae JW. The Effect of CYP2D6 Phenotypes on the Pharmacokinetics of Propafenone: A Systematic Review and Meta-Analysis. Pharmaceutics. 2022 Jul 11;14(7):1446.
Sunthankar SD, Kannankeril PJ, Gaedigk A, Radbill AE, Fish FA, Van Driest SL. Influence of CYP2D6 genetic variation on adverse events with propafenone in the pediatric and young adult population. Clin Transl Sci. 2022 Jul;15(7):1787-1795.
